Business
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®. The first-in-human Phase 1A
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®.\n\n\n\nThe first-in-human Phase 1A clinical trial has been cleared to proceed by the FDA and is anticipated to launch this summer for multiple advanced solid tumors and brain and central nervous system (CNS) cancers.\n\n\n\nLantern has been granted multiple Orphan Drug Designations by the FDA for LP-184 in pancreatic cancer, malignant gliomas, and atypical teratoid rhabdoid tumors (ATRT); in addition the FDA granted Rare Pediatric Disease Designation granted for LP-184 in ATRT.\n\n\n\nThe cancer indications being pursued for LP-184 are estimated to have an annual market potential of $11-13 billion; $6-7 billion for solid tumors and $5-6 billion for brain and CNS cancers.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (\"AI\") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during the current quarter.\n\n\n“The clearance of the IND application is a significant milestone for our LP-184 program and validates our approach of leveraging AI and machine learning to advance our pipeline of novel drug candidates,” stated Panna Sharma, Lantern’s CEO and President. “Insights from our AI platform RADR® were instrumental in our development of LP-184 and aided in discovering its mechanism of action, identifying and prioritizing its cancer indications, and generating machine learning biomarker signatures to assist with future clinical trial patient selection. We believe LP-184 has blockbuster potential for patients with multiple types of advanced solid tumors and CNS cancers, many of which have no or limited effective therapeutic options,” continued Sharma.\n\n\nLP-184 is the first of Lantern’s drug candidates to be developed entirely internally, with the assistance of Lantern’s AI and ML platform RADR®, to ...